Fibrates revisited: Potential role in cardiovascular risk reduction

Nam Hoon Kim, Sin Gon Kim

    Research output: Contribution to journalReview articlepeer-review

    44 Citations (Scopus)


    Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an “add on” to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.

    Original languageEnglish
    Pages (from-to)213-221
    Number of pages9
    JournalDiabetes and Metabolism Journal
    Issue number2
    Publication statusPublished - 2020 Apr

    Bibliographical note

    Publisher Copyright:
    © 2020 Korean Diabetes Association


    • Cardiovascular diseases
    • Dyslipidemias
    • Hydroxymethylglutaryl-CoA reductase inhibitors
    • Metabolic syndrome
    • PPAR alpha
    • Peroxisome proliferator-activated receptors

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism


    Dive into the research topics of 'Fibrates revisited: Potential role in cardiovascular risk reduction'. Together they form a unique fingerprint.

    Cite this